Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

Article  PubMed  Google Scholar 

Fisusi FA, Akala EO. Drug combinations in breast cancer therapy. Pharm Nanotechnol. 2019;7(1):3–23. https://doi.org/10.2174/2211738507666190122111224.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976;294(8):405–10. https://doi.org/10.1056/NEJM197602192940801.

Article  CAS  PubMed  Google Scholar 

Grunberg SM, Warr D, Gralla RJ, Rapoport BL, Hesketh PJ, Jordan K, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art. Support Care Cancer. 2011;19(Suppl 1):S43–7. https://doi.org/10.1007/s00520-010-1003-x.

Article  PubMed  Google Scholar 

Adel N. Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies. Am J Manag Care. 2017;23(14 Suppl):S259–S65.

PubMed  Google Scholar 

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Antiemesis - Version 1. 2021. 2020. https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients. Accessed 7 April 2021.

Aapro M, Scotte F, Escobar Y, Celio L, Berman R, Franceschetti A, et al. Practice patterns for prevention of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence based on real-world prescribing data. Oncologist. 2021;26(6):e1073–e82. https://doi.org/10.1002/onco.13716.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, et al. Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci. 2021;22(23). https://doi.org/10.3390/ijms222312808.

Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76(3):391–6.

PubMed  Google Scholar 

Rendic S, Guengerich FP. Survey of human oxidoreductases and cytochrome P450 enzymes involved in the metabolism of xenobiotic and natural chemicals. Chem Res Toxicol. 2015;28(1):38–42. https://doi.org/10.1021/tx500444e.

Article  CAS  PubMed  Google Scholar 

Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol. 2017;83(10):2148–62. https://doi.org/10.1111/bcp.13322.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Linardi A, Damiani D, Longui CA. The use of aromatase inhibitors in boys with short stature: what to know before prescribing? Arch Endocrinol Metab. 2017;61(4):391–7. https://doi.org/10.1590/2359-3997000000284.

Article  PubMed  PubMed Central  Google Scholar 

Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother. 1995;29(6):619–24. https://doi.org/10.1177/106002809502900612.

Article  CAS  PubMed  Google Scholar 

Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer. 2006;6(7):546–58. https://doi.org/10.1038/nrc1887.

Article  CAS  PubMed  Google Scholar 

Zhu BT. On the general mechanism of selective induction of cytochrome P450 enzymes by chemicals: some theoretical considerations. Expert Opin Drug Metab Toxicol. 2010;6(4):483–94. https://doi.org/10.1517/17425250903578642.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deb S, Pandey M, Adomat H, Guns ES. Cytochrome P450 3A-mediated microsomal biotransformation of 1alpha,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism. Drug Metab Dispos. 2012;40(5):907–18. https://doi.org/10.1124/dmd.111.041681.

Article  CAS  PubMed  Google Scholar 

Deodhar M, Al Rihani SB, Arwood MJ, Darakjian L, Dow P, Turgeon J, et al. Mechanisms of CYP450 inhibition: understanding drug-drug interactions due to mechanism-based inhibition in clinical practice. Pharmaceutics. 2020;12(9). https://doi.org/10.3390/pharmaceutics12090846.

Deb S, Reeves AA. Simulation of Remdesivir pharmacokinetics and its drug interactions. J Pharm Pharm Sci. 2021;24:277–91. https://doi.org/10.18433/jpps32011.

Article  CAS  PubMed  Google Scholar 

Deb S, Reeves AA, Lafortune S. Simulation of physicochemical and pharmacokinetic properties of vitamin D3 and its natural derivatives. Pharmaceuticals (Basel). 2020;13(8). https://doi.org/10.3390/ph13080160.

SimulationsPlus. GastroPlus Simulation Software for Drug Discovery and Development Manual. https://www.simulations-plus.com/ Accessed 10 Jan 2022.

Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N. Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification. Drug Metab Dispos. 2015;43(11):1823–37. https://doi.org/10.1124/dmd.115.065920.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Center for Drug Evaluation and Research. Physiologically based pharmacokinetic analyses - format and content. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/physiologically-based-pharmacokinetic-analyses-format-and-content-guidance-industry. Accessed 27 May 2022.

Kato M, Chiba K, Horikawa M, Sugiyama Y. The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes. Drug Metab Pharmacokinet. 2005;20(4):236–43. https://doi.org/10.2133/dmpk.20.236.

Article  CAS  PubMed  Google Scholar 

Marechal JD, Yu J, Brown S, Kapelioukh I, Rankin EM, Wolf CR, et al. In silico and in vitro screening for inhibition of cytochrome P450 CYP3A4 by comedications commonly used by patients with cancer. Drug Metab Dispos. 2006;34(4):534–8. https://doi.org/10.1124/dmd.105.007625.

Article  CAS  PubMed  Google Scholar 

Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin a oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol. 1992;41(6):1047–55.

CAS  PubMed  Google Scholar 

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer -Version 3. 2021. 2021. https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients. Accessed 7 April 2021.

Information NCfB. PubChem. 2021. https://pubchem.ncbi.nlm.nih.gov/ Accessed 28 March 2021.

Giuliano CLE, Funk C, Potthast M, Pietra C. In vitro drug-drug interaction studies with the antiemetic drug Netupitant and its major metabolites M1 and M2, involving several human cytochrome P450 isoenzymes. Ann Oncol. 2012;23:ix520. https://doi.org/10.1016/S0923-7534(20)34168-5.

Article  Google Scholar 

Sanchez RI, Wang RW, Newton DJ, Bakhtiar R, Lu P, Chiu SH, et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004;32(11):1287–92. https://doi.org/10.1124/dmd.104.000216.

Article  CAS  PubMed  Google Scholar 

Gervasini G, Caballero MJ, Carrillo JA, Benitez J. Comparative cytochrome p450 in vitro inhibition by atypical antipsychotic drugs. ISRN Pharmacol. 2013;2013:792456. https://doi.org/10.1155/2013/792456.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol. 1996;41(3):181–6. https://doi.org/10.1111/j.1365-2125.1996.tb00180.x.

Article  CAS  PubMed  Google Scholar 

Backman JT, Filppula AM, Niemi M, Neuvonen PJ. Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016;68(1):168–241. https://doi.org/10.1124/pr.115.011411.

Article  PubMed  Google Scholar 

Therapeutic Goods Administration (TGA) Australian Government Department of Health. Australian Public Assessment Report (AusPAR) for Netupitant / palonosetron (as hydrochloride). 2016. https://www.tga.gov.au/sites/default/files/auspar-netupitant-161028.pdf. Accessed 27 May 2022.

Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s). Rolapitant hydrochloride. 2014. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206500Orig1s000ClinPharmR.pdf. Accessed 27 May 2022.

Bloomer JC, Baldwin SJ, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol. 1994;38(6):557–66. https://doi.org/10.1111/j.1365-2125.1994.tb04397.x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fischer V, Vickers AE, Heitz F, Mahadevan S, Baldeck JP, Minery P, et al. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos. 1994;22(2):269–74.

CAS  PubMed  Google Scholar 

Center for Drug Evaluation and Research. Multi-discipline Review Fosnetupitant. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210493Orig1s000MultidisciplineR.pdf. Accessed 27 May 2022.

Sanwald P, David M, Dow J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos. 1996;24(5):602–9.

CAS  PubMed  Google Scholar 

Desta Z, Wu GM, Morocho AM, Flockhart DA. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos. 2002;30(3):336–43. https://doi.org/10.1124/dmd.30.3.336.

Article  CAS  PubMed  Google Scholar 

Basak D, Arrighi S, Darwiche Y, Deb S. Comparison of anticancer drug toxicities: paradigm shift in adverse effect profile. Life (Basel). 2021;12(1). https://doi.org/10.3390/life12010048.

Mudd TW, Guddati AK. Management of hepatotoxicity of chemotherapy and targeted agents. Am J Cancer Res. 2021;11(7):3461–74.

CAS  PubMed  PubMed Central  Google Scholar 

Tao JJ, Visvanathan K, Wolff AC. Long term side effects of adjuvant chemotherapy in patients with early breast cancer. Breast. 2015;24(Suppl 2):S149–53. https://doi.org/10.1016/j.breast.2015.07.035.

Article  PubMed  Google Scholar 

Celgene Corp. Abraxane (paclitaxel protein-bound particles for injectable suspension). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021660s047lbl.pdf. Accessed 27 May 2022.

Pfizer Inc. Doxorubicin Hydrochloride Package Insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050467s073lbl.pdf. Accessed 27 May 2022.